

RAYZON BIOCARE PRIVATE LIMITED

CIN: U24299GJ2021PTC127862

ADDRESS

Block No-105, Nr. Hariya Talav,
B/h. Aron Pipes, Vill-Karanj, Ta-
Mandavi, Surat-394110

AUDIT REPORT

FOR

FINANCIAL YEAR: 2022-23

AUDITOR

K D KANANI & CO

Chartered Accountants

B-28, Divya Vasundhara Flats,
Nr. Panchwati Wadi,
L. H. Road,
Surat-395010.

Phone: 9537688983

E-mail: kananikaushik_ca@yahoo.com

INDEPENDENT AUDITOR'S REPORT

TO THE MEMBERS OF
RAYZON BIOCARE PRIVATE LIMITED

Report on the Audit of the Financial Statements

Opinion

- 1 We have audited the financial statements of RAYZON BIOCARE PRIVATE LIMITED ('the Company'), which comprise the Balance Sheet as at 31st March, 2023, the Statement of Profit and Loss for the year then ended, Statement of Cash Flows and notes to the financial statements, including a summary of significant accounting policies and other explanatory information.
- 2 In our opinion, and to the best of our information and according to the explanations given to us, the aforesaid financial statements give the information required by the Act in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of the state of affairs of the Company as at 31st March, 2023 and its profit/loss and its cash flows for the year ended on that date.

Basis for Opinion

- 3 We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013 ('the Act'). Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Information other than the Financial Statements and Auditor's Report thereon

- 4 The Company's Board of Directors is responsible for the other information. The other information comprises the information included in the Directors Report including Annexures to Directors Report, but does not include the financial statements and our auditor's report thereon.



INDEPENDENT AUDITOR'S REPORT

TO THE MEMBERS OF
RAYZON BIOCARE PRIVATE LIMITED

- 5 Our opinion on the financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.
- 6 In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Responsibilities of Management and Those Charged with Governance for the Financial Statements

- 7 The Company's Board of Directors is responsible for the matters stated in section 134(5) of the Act with respect to the preparation of these financial statements that give a true and fair view of the financial position and financial performance and cash flows of the Company in accordance with the accounting principles generally accepted in India, including the Accounting Standards specified under section 133 of the Act. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.
- 8 In preparing the financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations or has no realistic alternative but to do so.
- 9 Those Board of Directors are also responsible for overseeing the company's financial reporting process.



INDEPENDENT AUDITOR'S REPORT

TO THE MEMBERS OF
RAYZON BIOCARE PRIVATE LIMITED

Auditor's Responsibilities for the Audit of the Financial Statements

- 10 Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.
- 11 As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:
 - 11.1 Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
 - 11.2 Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the Company has adequate internal financial controls system in place and the operating effectiveness of such controls.
 - 11.3 Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
 - 11.4 Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.



INDEPENDENT AUDITOR'S REPORT

**TO THE MEMBERS OF
RAYZON BIO CARE PRIVATE LIMITED**

- 11.5 Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.
- 12 We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.
- 13 We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Report on other Legal and Regulatory Requirements

- 14 This report does not include a statement on the matters specified in paragraphs 3 and 4 of the Companies (Auditor's Report) Order, 2020 ('the Order') issued by the Central Government of India, in terms of section 143(11) of the Act, since in our opinion and according to the information and explanations given to us, the said Order is not applicable to the Company.
- 15 As required by section 143(3) of the Act, we report that:
- We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit;
 - In our opinion, proper books of account as required by law have been kept by the Company, so far as it appears from our examination of those books;
 - The Balance Sheet, the Statement of Profit and Loss and the Cash Flow Statement dealt with by this Report are in agreement with the books of account;
 - In our opinion, the aforesaid financial statements comply with the Accounting Standards specified under section 133 of the Act, read with rule 7 of the Companies (Accounts) Rules, 2014;



INDEPENDENT AUDITOR'S REPORT

**TO THE MEMBERS OF
RAYZON BIOCARE PRIVATE LIMITED**

- e) On the basis of the written representations received from the Directors, as on 31st March, 2023, taken on record by the Board of Directors, none of the Directors is disqualified as on 31st March, 2023, from being appointed as a Director in terms of section 164(2) of the Act;
- f) The Company is a private company and its turnover did not exceed Rs. 50 crore during the previous year or the aggregate borrowings from banks or financial institutions or any body corporate did not exceed Rs. 25 crore at any point of time during the financial year. As per Notification No. G.S.R. 583(E) dated 13th June, 2017 read with General Circular No. 08/2017 dated 25th July, 2017 issued by the Ministry of Corporate Affairs, we are not required to report in respect of the adequacy of the internal financial controls over financial reporting of the Company and the operating effectiveness of such controls under section 143(3)(i) of the Act.
- g) With respect to the other matters to be included in the Auditor's Report in accordance with rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:
- i. The Company does not have any pending litigations which would impact its financial position.
- ii. The Company did not have any long-term contracts including derivative contracts for which there were any material foreseeable losses.
- iii. The Company is not required to transfer any amount to the Investor Education and Protection Fund.
- iv. A. The Company has not advanced or loaned or invested funds (either borrowed funds or share premium or any other sources or kind of funds) to any other person(s) or entity(ies), including foreign entities (Intermediaries) during the year with the understanding (whether recorded in writing or otherwise) that the Intermediary shall:
- (a) directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Company (Ultimate Beneficiaries) or



K D KANANI & CO
Chartered Accountants

Kaushik D Kanani
B.Com., ACA (ICAI)

B-28, Divya Vasundhara Flats,
Nr. Panchwati Wadi,
L. H. Road,
Surat-395010.
Phone: 9537688983

INDEPENDENT AUDITOR'S REPORT

**TO THE MEMBERS OF
RAYZON BIOCARE PRIVATE LIMITED**

- (b) provide any guarantee, security or the like to or on behalf of the Ultimate Beneficiaries.
- B. The management has represented, that, to the best of its knowledge and belief, no funds have been received by the Company from any persons or entities, including foreign entities ("Funding Parties"), with the understanding, whether recorded in writing or otherwise, that the Company shall:
 - (a) directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever ("Ultimate Beneficiaries") by or on behalf of the Funding Party or
 - (b) provide any guarantee, security or the like from or on behalf of the Ultimate Beneficiaries; and
- C. Based on such audit procedures as considered reasonable and appropriate in the circumstances, nothing has come to our notice that has caused us to believe that the representations under subclause (iv)(A) and (iv)(B) contain any material misstatement.
- v. The Company has not declared or paid any dividend during the year and has not proposed final dividend for the year.

Place: Surat
Date: September 02, 2023



For K D KANANI & CO
Chartered Accountants
Firm Reg No. 147212W

A handwritten signature in blue ink, appearing to read "Kaushik D Kanani".

Kaushik D Kanani
Proprietor

M. No. 183787

UDIN: 23183787BGXDWQ3768

RAYZON BIOCARE PRIVATE LIMITED

FINANCIAL YEAR: 2022-23

APPLICABILITY OF REPORT ON INTERNAL FINANCIAL CONTROLS

Conditions:

Rs. in lakh

Chapter X clause (i) of sub-section (3) of section 143

- | | | | |
|---|--|-----|-----|
| a | Whether private limited company? | Yes | Yes |
| b | Turnover does not exceed Rs. 50 crores during previous year | 0 | Yes |
| c | Aggregate borrowings from banks or financial institution or any other body corporate does not exceed Rs. 25 crores | 0 | Yes |

All the conditions are fulfilled. Hence, reporting on IFC is not required.



RAYZON BIOCARE PRIVATE LIMITED

FINANCIAL YEAR: 2022-23

APPLICABILITY OF CARO, 2020

Conditions:

(Rs. in lakh)

Clause 1(2)(iv)

Whether small company u/s. 2(85)?

- | | | | |
|---|---------------------------------------|---------|----------|
| a | Whether private limited company? | Yes | Yes |
| b | Paid-up capital do not exceed Rs. 2 | Capital | 2.00 Yes |
| c | Turnover does not exceed Rs. 20 crore | 0 | Yes |

All the conditions are fulfilled. Hence, the provisions of CARO, 2020 are not applicable.

Or

Clause 1(2)(v)

(Rs. in lakh)

- | | | | |
|---|---|-----------------------------|-------------|
| a | Whether private limited company? | Yes | Yes |
| b | Paid-up capital and reserves do not exceed Rs. 1 crore | Capital | 2.00 |
| | | State cash subsidy | 0 |
| | | Profit & Loss a/c - surplus | (13.55) |
| | | Net worth | (11.55) Yes |
| c | Outstanding loan from any bank or financial institution do not exceed Rs. 1 crore | 0 | Yes |
| d | Total revenue does not exceed Rs. 10 crore | 5.43 | Yes |

All the conditions are fulfilled. Hence, the provisions of CARO, 2020 are not applicable.



RAYZON BIOCARE PRIVATE LIMITED

BALANCE SHEET AS AT 31ST MARCH, 2023

(Rupees in lakh)

Particulars	Note	As at 31-03-2023	As at 31-03-2022
EQUITY AND LIABILITIES			
Shareholders' funds			
Share capital	2	2.00	2.00
Reserves and surplus	3	(13.55)	0.00
		(11.55)	2.00
Non-current liabilities			
Long-term borrowings	4	69.00	0.00
		69.00	0.00
Current liabilities			
Trade payables:	5		
a) Total outstanding dues of creditors other than micro enterprises and		1.41	0.00
Other current liabilities	6	1.78	0.00
		3.20	0.00
Total		60.65	2.00

ASSETS

Non-current assets

Property, plant and equipment and intangible assets:

a) Property, plant and equipment	7	0.20	0.00
Deferred tax assets (Net)	8	0.00	0.00
Other non-current assets	9	3.07	0.00
		3.26	0.00

Current assets

Inventories	10	44.38	0.00
Trade receivables	11	0.32	0.00
Cash and bank balances	12	1.66	0.91
Short-term loans and advances	13	0.60	0.85
Other current assets	14	10.42	0.24
		57.39	2.00
Total		60.65	2.00



FOR, RAYZON BIOCARE PVT. LTD.

 DIRECTOR

FOR, RAYZON BIOCARE PVT. LTD.

 DIRECTOR

RAYZON BIOCARE PRIVATE LIMITED

BALANCE SHEET AS AT 31ST MARCH, 2023

(Rupees in lakh)

Particulars	Note	As at 31-03-2023	As at 31-03-2022
Additional Regulatory Information	15		
Significant accounting policies	1		
See accompanying notes to the financial s 25 to 26			

As per our report attached


For K D KANANI & CO
Chartered Accountants
Firm Reg No. 147212W




Kaushik D Kanani
Proprietor
M. No. 183787



For and on behalf of the Board


Chirag Devchandbhai Nakrani
Director
DIN: 08589167


Hardik Ashokbhai Kothiya
Director
DIN: 08589174

Place: Surat
Date: September 02, 2023

Place: Surat
Date: September 02, 2023

RAYZON BIOCARE PRIVATE LIMITED

STATEMENT OF PROFIT AND LOSS FOR THE YEAR ENDED 31ST MARCH, 2023

		(Rupees in lakh)	
Particulars	Note	2022-23	2021-22
Income			
Revenue from operations	16	5.40	0.00
Other income	17	0.04	0.00
Total income		<u>5.43</u>	<u>0.00</u>
Expenses			
Purchases of stock-in-trade	18	48.38	0.00
Changes in stock-in-process and stock-in-trade	19	(44.38)	0.00
Trading expenses	20	1.16	0.00
Employee benefits expense	21	0.25	0.00
Finance costs	22	0.02	0.00
Depreciation and amortisation expense	7	0.05	0.00
Other expenses	23	13.51	0.00
Total expenses		<u>18.98</u>	<u>0.00</u>
Profit/(Loss) before tax		(13.55)	0.00
Tax expense			
Deferred tax		(0.00)	0.00
Profit/(Loss) after tax		(13.55)	0.00
Earnings per equity share (Face value: Rs. 10)			
Basic	24	(67.73)	0.00
Diluted	24	(67.73)	0.00

Significant accounting policies 1
See accompanying notes to the financial statements 25 to 26

As per our report attached to balance sheet


For K D KANANI & CO
Chartered Accountants
Firm Reg No. 147212W



Kaushik D Kanani
Proprietor
M. No. 183787



For and on behalf of the Board


Chirag Devchandbhai Nakrani
Director
DIN: 08589167



Hardik Ashokbhai Kothiya
Director
DIN: 08589174

Place: Surat
Date: September 02, 2023

Place: Surat
Date: September 02, 2023


RAYZON BIOCARE PRIVATE LIMITED

CASH FLOW STATEMENT FOR THE YEAR ENDED 31ST MARCH, 2023

	(Rupees in lakh)	
	2022-23	2021-22
A. CASH FLOW FROM OPERATING ACTIVITIES		
Net profit before tax and extraordinary items	(13.55)	0.00
Adjustments for:		
Depreciation and amortisation expenses	0.05	0.00
Finance costs	0.02	0.00
Interest income	(0.04)	0.00
Operating profit before working capital changes	(13.50)	0.00
Adjustments for:		
Increase / (decrease) in trade and other receivables	(13.32)	(1.09)
Increase / (decrease) in inventories	(44.38)	0.00
Increase/(decrease) in trade payables, other liabilities and pre	3.20	0.00
Cash generated from operations	(68.01)	(1.09)
Taxes paid	0.00	0.00
Net cash flow from / (used in) operating activities	(68.01)	(1.09)
B. CASH FLOW FROM INVESTING ACTIVITIES		
Purchase of property, plant and equipment	(0.25)	0.00
Net cash used in investing activities	(0.25)	0.00
C. CASH FLOW FROM FINANCING ACTIVITIES		
Proceeds from issue of share capital	0.00	2.00
Proceeds from long-term borrowings	69.00	0.00
Interest & other borrowing costs	(0.02)	0.00
Interest received from others	0.04	0.00
Net cash used in financing activities	69.01	2.00
NET INCREASE IN CASH AND CASH EQUIVALENT (A+B+C)	0.75	0.91
Cash and cash equivalents as at beginning (Opening balance)	0.91	0.00
Cash and cash equivalents as at end of the year (Closing balance)	1.66	0.91
Net increase/ decrease	0.75	0.91


As per our report attached to balance sheet

For K D KANANI & CO
Chartered Accountants
Firm Reg No. 147212W


Kaushik D Kanani
Proprietor
M. No. 183787



For and on behalf of the Board


Chirag Devchandbhai Nakrani
Director
DIN: 08589167


Hardik Ashokbhai Kothiya
Director
DIN: 08589174

Place: Surat
Date: September 02, 2023

Place: Surat
Date: September 02, 2023

RAYZON BIOCARE PRIVATE LIMITED

NOTES TO FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH, 2023

NOTE 1

SIGNIFICANT ACCOUNTING POLICIES

1 Corporate information

RAYZON BIOCARE PRIVATE LIMITED (the 'Company') is a private limited Company domiciled in India having CIN: U24299GJ2021PTC127862. The registered office of the Company is located at Block No-105, Nr. Hariya Talav, B/h. Aron Pipes, Vill-Karanj, Ta-Mandavi, Surat-394110. The Company is engaged in the business of Trading of cosmetic Item.

2 Basis of preparation of financial statements:

The financial statements are prepared under the historical cost convention in accordance with the generally accepted accounting principles in India and the provisions of the Companies Act, 2013.

All assets and liabilities have been classified as current and non-current as per the company's normal operating cycle. Based on the nature of products and time elapsed between deployment of resources and the realisation in cash and cash equivalents of the consideration for such goods sold, the Company has considered an operating cycle of 12 months.

The preparation of financial statements requires estimates and assumptions to be made that affect the reported amount of assets and liabilities on the date of the financial statements and the reported amount of revenues and expenses during the reporting period. Difference between the actual results and estimates are recognised in the period in which the results are known / materialised.



The Company is a Small and Medium Sized Company (SMC) as defined in the Companies (Accounting Standards) Rules, 2021 notified under the Companies Act, 2013. Accordingly, the Company has complied with the Accounting Standards as applicable to a Small and Medium Sized Company.

3 Significant accounting policies

a Revenue recognition:

Revenue from sale of traded goods is recognised when the substantial risks and rewards of ownership are transferred to the buyer under the terms of the contract and a reasonable expectation of collection of the sale consideration from the customer exists.

Interest income is recognised on a time proportion basis taking into account the amount outstanding and the rate applicable.



RAYZON BIOCARE PRIVATE LIMITED

NOTES TO FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH, 2023

NOTE 1

SIGNIFICANT ACCOUNTING POLICIES

Dividend income is recognised when right to receive is established.

Rent on immovable properties is recognised on accrual basis as per the agreement with the party.

b Property, plant and equipment:

Property, plant and equipment are stated at cost net of recoverable taxes, trade discount and rebates, less accumulated depreciation and impairment losses, if any. Cost comprises the purchase price, including duties and other non-refundable taxes or levies and directly attributable cost of bringing the asset to its working condition and indirect costs specifically attributable to construction of a project or to the acquisition of fixed asset. Subsequent expenditure related to an item of tangible asset are added to its book value only if they increase the future benefits from the existing asset beyond its previously assessed standard of performance. Assets retired from active use are carried at lower of book value and estimated net realisable value.

c Depreciation and amortisation:

i) The Company provides for depreciation on tangible assets to the extent of depreciable amount on written down value method. Depreciation is provided based on useful life and residual value of the assets as prescribed in Schedule II to the Companies Act, 2013.

ii) Depreciation on additions to assets or on sale / discardment of assets is provided on pro rata basis from the month in which assets have been put to use, up to the month prior to the month in which assets have been disposed off. Depreciation on additions to assets is provided over the residual life of the respective asset.

iii) Cost of Leasehold Land is amortised over the period of lease.

d Impairment of assets:

An asset is treated as impaired when the carrying cost of asset exceeds its recoverable value. An impairment loss is charged to the Statement of Profit and Loss in the year in which an asset is identified as impaired. The impairment loss recognised in prior accounting period is reversed, if there has been a change in the estimate of recoverable amount.

e Investments:

Investments are classified into current and long-term investments. Current investments are stated at lower of cost and fair value. Long-term investments are stated at cost. A provision for diminution is made to recognise a decline, other than temporary, in the value of long-term investments.



FOR, RAYZON BIOCARE PVT. LTD.

[Signature]

DIRECTOR

FOR, RAYZON BIOCARE PVT. LTD.

[Signature]

DIRECTOR

RAYZON BIOCARE PRIVATE LIMITED

NOTES TO FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH, 2023

NOTE 1

SIGNIFICANT ACCOUNTING POLICIES

f Inventories:

The inventories are valued at lower of cost or net realisable value, using first in first out formula. Cost of inventories comprises of cost of purchase and manufacturing costs incurred in bringing them to their respective present location and condition. Stock-in-process and finished goods are valued after considering direct overheads.

g Foreign currency transactions:

i) Transactions denominated in foreign currencies are recorded at the exchange rate prevailing on the date of the transaction or that approximates the actual rate at the date of the transaction.

ii) Monetary items denominated in foreign currencies at the year end are restated at year end rates. In case of items which are covered by forward exchange contracts, the difference between the year end rate and rate on the date of the contract is recognised as exchange difference and the premium paid on forward contracts is recognised over the life of the contract.

iii) Non-monetary foreign currency items are carried at cost.

iv) Any income or expense on account of exchange difference either on settlement or on translation is recognised in the Statement of Profit and Loss except in case of long term liabilities, where they relate to acquisition of fixed assets, in which case they are adjusted to the carrying cost of such assets.

h Employee benefits:

Wages, salaries, paid annual leave, sick leave and bonuses are accrued in the year in which the services are rendered by the employees. The company does not permit accumulating of unused leaves. The company does not provide any long-term employee benefits except gratuity.

Gratuity liability for eligible employees is defined benefit obligation and are provided for on the basis of an actuarial valuation on projected unit credit method made at the end of each financial year. Obligation is measured at the present value of estimated future cash flows using discounted rate that is determined by reference to market yields at the Balance Sheet date on Government Securities where the currency and terms of the Government Securities are consistent with the currency and estimated terms of the defined benefit obligation. Actuarial gains/losses are immediately taken to Statement of Profit and Loss.

The contributions to defined contribution plans are charged to the statement of profit and loss.



FOR, RAYZON BIOCARE PVT. LTD.
[Signature]
DIRECTOR

FOR, RAYZON BIOCARE PVT. LTD.
[Signature]
DIRECTOR

RAYZON BIOCARE PRIVATE LIMITED

NOTES TO FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH, 2023

NOTE 1

SIGNIFICANT ACCOUNTING POLICIES

i Borrowing cost:

Borrowing cost attributable to the acquisition or construction of qualifying assets are capitalised as part of the cost of such assets. A qualifying asset is one that necessarily takes substantial period of time to get ready for its intended use. All other borrowing costs are charged to revenue.

j Taxation:

Provision for current tax is made after taking into consideration benefits admissible under the provisions of the Income-tax Act, 1961.

Deferred tax resulting from timing difference between taxable income and accounting income is accounted for using the tax rates and laws that have been enacted or substantially enacted as on the balance sheet date. The deferred tax asset is recognised and carried forward only to the extent that there is a reasonable certainty that the assets will be realised in future.

k Provisions, contingent liabilities and contingent assets:

Provisions involving substantial degree of estimation in measurement are recognized when there is a present obligation as a result of past events and it is probable that there will be an outflow of resources. Contingent liabilities are not recognised but are disclosed in the notes. Contingent assets are neither recognized nor disclosed in the financial statements.

l Earnings per share

Basic earnings per equity share is computed by dividing the net profit attributable to the equity holders of the Company by the weighted average number of equity shares outstanding during the period. Diluted earnings per equity share is computed by dividing the net profit attributable to the equity holders of the Company by the weighted average number of equity shares considered for deriving basic earnings per equity share and also the weighted average number of equity shares that could have been issued upon conversion of all dilutive potential equity shares. The dilutive potential equity shares are adjusted for the proceeds receivable had the equity shares been actually issued at fair value. Dilutive potential equity shares are deemed converted as at the beginning of the period, unless issued at a later date. Dilutive potential equity shares are determined independently for each period presented.



FOR, RAYZON BIOCARE PVT. LTD.
[Signature]
DIRECTOR

FOR, RAYZON BIOCARE PVT. LTD.
[Signature]
DIRECTOR

RAYZON BIOCARE PRIVATE LIMITED

NOTES TO FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH, 2023

Particulars	(Rupees in lakh)	
	As at 31-03-2023	As at 31-03-2022
	Rupees	Rupees

NOTE 2

SHARE CAPITAL

a Authorised

100000 Equity Shares of Rs. 10 each (Previous year 100000 Equity Shares)	10.00	10.00
---	-------	-------

b Issued, subscribed and paid-up

20000 Equity Shares of Rs. 10 each fully paid-up (Previous year 20000 Equity Shares)	2.00	2.00
--	------	------

Total share capital	2.00	2.00
---------------------	------	------

c The reconciliation of the number of shares and share capital

Particulars	As at 31-03-2023		As at 31-03-2022	
	No. of shares	Amount (Rs in Lakh)	No. of shares	Amount (Rs in Lakh)
Equity Shares at the beginning of the ye	20000.00	2.00	0.00	0.00
Add: Shares issued	0.00	0.00	20000.00	2.00
Less: Shares cancelled on buy back	0.00	0.00	0.00	0.00
Equity Shares at the end of the year	20000.00	2.00	20000	2.00

d Terms / rights attached to Equity Shares

The Company has one class of Equity Shares each having par value of Rs. 10 per share. Each holder of Equity Shares is entitled to one vote per share. In the event of liquidation of the Company, the holders of Equity Shares will be entitled to receive the remaining assets of the Company, after distribution of all preferential amounts, in proportion of their shareholding.

e Shareholders holding more than 5 per cent of Equity Shares as at the end of the year

Name of the Shareholder	As at 31-03-2023		As at 31-03-2022	
	No. of shares	% of holding	No. of shares	% of holding
Chirag Devchandbhai Nakrani	6000.00	30.00	10000.00	50.00
Hardik Ashokbhai Kothiya	6000.00	30.00	10000.00	50.00
Gaurav Dhirubhai Nakarani	2500.00	12.50	0.00	0.00
Darshil Bharatbhai Gondaliya	2500.00	12.50	0.00	0.00
Sanketkumar Bharatbhai Kothiya	3000.00	15.00	0.00	0.00

FOR, RAYZON BIOCARE PVT. LTD.

DIRECTOR

[Signature]

FOR, RAYZON BIOCARE PVT. LTD.

DIRECTOR

[Signature]



RAYZON BIOCARE PRIVATE LIMITED

NOTES TO FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH, 2023

Particulars	(Rupees in lakh)		
	As at 31-03-2023	As at 31-03-2022	
	Rupees	Rupees	Rupees
NOTE 3			
RESERVES AND SURPLUS			
Statement of Profit and Loss - surplus:			
Balance as per last balance sheet	0.00	0.00	
Add/ (Less): Profit/ (Loss) for the year	(13.55)	0.00	
Closing balance	(13.55)	0.00	
	<u>(13.55)</u>	<u>0.00</u>	

NOTE 4
LONG-TERM BORROWINGS

Unsecured loans

Loans and advances from related parties	69.00	0.00
	<u>69.00</u>	<u>0.00</u>

NOTE 5
TRADE PAYABLES

a) Total outstanding dues of creditors other than micro enterprises and small enterprises	1.41	0.00
	<u>1.41</u>	<u>0.00</u>

NOTE 6
OTHER CURRENT LIABILITIES

Other payables:

Advances from customers	1.78	0.00
	<u>1.78</u>	<u>0.00</u>



FOR, RAYZON BIOCARE PVT. LTD.
[Signature]
DIRECTOR

FOR, RAYZON BIOCARE PVT. LTD.
[Signature]
DIRECTOR

RAYZON BIOCARE PRIVATE LIMITED

NOTES TO FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH, 2023

**NOTE 7
PROPERTY, PLANT AND EQUIPMENT**

Description	Gross Block at Cost			Depreciation and Impairment			(Rupees in lakh)	
	As at 01-04-2022	Addi- tions	Disposals 31-03-2023	As at 01-04-2022	Addi- tions	Impair- ment	As at 31-03-2023	Net Block As at 31-03-2023
Tangible assets								
Printer	0.00	0.10	0.00	0.00	0.03	0.00	0.03	0.07
Computer	0.00	0.15	0.00	0.00	0.03	0.00	0.03	0.13
Total	0.00	0.25	0.00	0.00	0.05	0.00	0.05	0.20

Description	Gross Block at Cost			Depreciation and Impairment			(Rupees in lakh)	
	As at 01-04-2021	Addi- tions	Disposals 31-03-2022	As at 01-04-2021	Addi- tions	Impair- ment	As at 31-03-2022	Net Block As at 31-03-2022
Tangible assets								
Printer	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Computer	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00



FOR, RAYZON BIOCARE PVT. LTD.
[Signature]
DIRECTOR

FOR, RAYZON BIOCARE PVT. LTD.
[Signature]
DIRECTOR

RAYZON BIOCARE PRIVATE LIMITED

NOTES TO FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH, 2023

Particulars	Rupees	As at	(Rupees in lakh)
		31-03-2023	As at 31-03-2022
		Rupees	Rupees

NOTE 8

DEFERRED TAX ASSETS (Net)

Deferred tax assets

Related to property, plant and equipment	0.00	0.00
Disallowances under the Income-tax Act, 1961	0.00	0.00
	<u>0.00</u>	<u>0.00</u>

NOTE 9

OTHER NON-CURRENT ASSETS

(Unsecured, considered good)

Security deposits	0.03	0.00
Others		
Bank deposits with maturity of more than 12 months	3.04	0.00
	<u>3.07</u>	<u>0.00</u>

NOTE 10

INVENTORIES

Stock-in-trade (in respect of goods acquired for trading)	44.38	0.00
	<u>44.38</u>	<u>0.00</u>

NOTE 11

TRADE RECEIVABLES

(Secured)

Considered good - secured	0.32	0.00
	<u>0.32</u>	<u>0.00</u>

NOTE 12

CASH AND BANK BALANCES

Cash and cash equivalents

Balances with banks	1.50	0.66
Cash on hand	0.16	0.25
	<u>1.66</u>	<u>0.91</u>



FOR, RAYZON BIOCARE PVT. LTD.

[Signature]
DIRECTOR

FOR, RAYZON BIOCARE PVT. LTD.

[Signature]
DIRECTOR

RAYZON BIOCARE PRIVATE LIMITED

NOTES TO FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH, 2023

Particulars				(Rupees in lakh)
		As at 31-03-2023	As at 31-03-2022	
	Rupees	Rupees	Rupees	Rupees
NOTE 13				
SHORT-TERM LOANS AND ADVANCES				
(Unsecured, considered good)				
Advances to suppliers		0.60		0.85
		<u>0.60</u>		<u>0.85</u>

NOTE 14
OTHER CURRENT ASSETS

Pre-paid expenses	0.16	0.21
Tax refunds receivable (Net)	<u>10.25</u>	<u>0.03</u>
	<u>10.42</u>	<u>0.24</u>



FOR, RAYZON BIOCARE PVT. LTD.
[Signature]
DIRECTOR

FOR, RAYZON BIOCARE PVT. LTD.
[Signature]
DIRECTOR

RAYZON BIOCARE PRIVATE LIMITED

NOTES TO FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH, 2023

NOTE 15

ADDITIONAL REGULATORY INFORMATION

1 Title deeds of immovable property not held in the name of the Company

Relevant line item in the Balance Sheet	Description of item of property	Gross carrying value Rs. in lakh	Title deeds held in the name of	Whether title deed holder is a promoter, director or relative of promoter / director or employee of promoter / director	Property held since which date	Reason for not being held in the name of the Company
PPE	Land	Nil	Nil	Nil	Nil	Nil
	Building	Nil	Nil	Nil	Nil	Nil
Investment property	Land	Nil	Nil	Nil	Nil	Nil
	Building	Nil	Nil	Nil	Nil	Nil
PPE retired from active use and held for disposal	Land	Nil	Nil	Nil	Nil	Nil
	Building	Nil	Nil	Nil	Nil	Nil
Others		Nil	Nil	Nil	Nil	Nil

2 Revaluation of property, plant and equipment

The Company has not revalued any of the property, plant and equipment during the year.

3 Loans or advances - Additional disclosures

The Company has not granted any loan or advance in nature of loan to promoters, directors, key managerial personnel and related parties as defined under the Companies Act, 2013 either severally or jointly with any other person that is (a) repayable on demand; or (b) without specifying any terms or period of repayment.

4 Capital work-in-progress (CWIP)

The Company is not having any capital work-in-progress during the year or previous year.



FOR, RAYZON BIOCARE PVT. LTD.

 DIRECTOR

FOR, RAYZON BIOCARE PVT. LTD.

 DIRECTOR

RAYZON BIOCARE PRIVATE LIMITED

NOTES TO FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH, 2023

5 Intangible assets under development

The Company is not having any intangible asset under development during the year or previous year.

6 Details of Benami Property held

No proceedings have been initiated or pending against the Company for holding any benami property under the Prohibition of Benami Property Transactions Act, 1988 (45 of 1988) and the rules made thereunder as amended from time to time.

7 Security of current assets against borrowings

The Company has no borrowings from banks or financial institutions on the basis of security of current assets at any point of time of the year. Hence, requirements of filing quarterly returns or statements of current assets by the Company with banks or financial institutions and providing summary of reconciliation and reasons of material discrepancies do not apply.

8 Wilful defaulter

The Company has no borrowings from banks or financial institutions or other lenders. However, the Company has not been declared a wilful defaulter at any time during the year or after the end of reporting period, but before the date when financial statements are approved or in an earlier period and the default has continued for the whole or part of the current year by any bank or financial institution or other lender.

Relationship with Struck off companies

The Company has no transaction during the year with companies struck off under section 248 of the Companies Act, 2013 or section 560 of the Companies Act, 1956.

10 Registration of charges or satisfaction with Registrar of Companies

There are no charges or satisfaction yet to be registered with Registrar of Companies beyond the statutory period.

11 Compliance with number of layers of companies

The Company is not having any subsidiary. Hence, requirement of compliance with the number of layers prescribed under clause (87) of section 2 of the Act read with Companies (Restriction on number of Layers) Rules, 2017 is not applicable

12 Compliance with approved Scheme(s) of Arrangements

No Scheme of Arrangements has been approved by the Competent Authority in terms of sections 230 to 237 of the Companies Act, 2013 during the year. Hence, the requirements of disclosure of effect of such Scheme of Arrangements in the books of account in accordance with the Scheme and in accordance with accounting standards are not applicable.

FOR, RAYZON BIOCARE PVT. LTD.
DIRECTOR

FOR, RAYZON BIOCARE PVT. LTD.
DIRECTOR




RAYZON BIOCARE PRIVATE LIMITED

NOTES TO FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH, 2023

13 Utilisation of Borrowed funds and share premium

- (A) The Company has not advanced or loaned or invested funds (either borrowed funds or share premium or any other sources or kind of funds) to any other person(s) or entity(ies), including foreign entities (Intermediaries) during the year with the understanding (whether recorded in writing or otherwise) that the Intermediary shall:
- (i) directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Company (Ultimate Beneficiaries) or
 - (ii) provide any guarantee, security or the like to or on behalf of the Ultimate Beneficiaries.
- (B) The Company has not received any fund from any person(s) or entity(ies), including foreign entities (Funding Party) during the year with the understanding (whether recorded in writing or otherwise) that the Company shall:
- (i) directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party (Ultimate Beneficiaries) or
 - (ii) provide any guarantee, security or the like to or on behalf of the Ultimate Beneficiaries.



RAYZON BIOCARE PRIVATE LIMITED

NOTES TO FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH, 2023

Particulars	2022-23	(Rupees in lakh) 2021-22
-------------	---------	-----------------------------

NOTE 16

REVENUE FROM OPERATIONS

Sale of products	5.40	0.00
	<u>5.40</u>	<u>0.00</u>

NOTE 17

OTHER INCOME

Interest income	0.04	0.00
	<u>0.04</u>	<u>0.00</u>

NOTE 18

PURCHASES OF STOCK-IN-TRADE

Purchases	<u>48.38</u>	<u>0.00</u>
-----------	--------------	-------------

NOTE 19

CHANGES IN STOCK-IN-PROCESS AND STOCK-IN-TRADE

Closing stock:			
Stock-in-trade	<u>44.38</u>	<u>0.00</u>	
	44.38		0.00
Less: Opening stock:			
Stock-in-trade	<u>0.00</u>	<u>0.00</u>	
	0.00		0.00
	<u>(44.38)</u>	<u>0.00</u>	

NOTE 20

TRADING EXPENSES

Freight inward charges	<u>1.16</u>	<u>0.00</u>
	<u>1.16</u>	<u>0.00</u>

NOTE 21

EMPLOYEE BENEFITS EXPENSES

Salary and allowances	0.25	0.00
	<u>0.25</u>	<u>0.00</u>

FOR, RAYZON BIOCARE PVT. LTD.
DIRECTOR

[Signature]

FOR, RAYZON BIOCARE PVT. LTD.
DIRECTOR

[Signature]



RAYZON BIOCARE PRIVATE LIMITED

NOTES TO FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH, 2023

Particulars	(Rupees in lakh)	
	2022-23	2021-22
NOTE 22		
FINANCE COSTS		
Interest expenses	0.02	0.00
	<u>0.02</u>	<u>0.00</u>

NOTE 23 OTHER EXPENSES

Professional fees	0.34	0.00
Auditors' remuneration (As per Note 23.1)	0.13	0.00
Miscellaneous expenses	3.08	0.00
Other selling and distribution expenses	9.97	0.00
	<u>13.51</u>	<u>0.00</u>

NOTE 23.1 AUDITORS' REMUNERATION

Audit fees	0.13	0.00
	<u>0.13</u>	<u>0.00</u>

NOTE 24 EARNINGS PER SHARE

i) Basic

Number of equity shares as at 01-04-2022	20000	0
Number of equity shares as at 31-03-2023	20000	20000
Number of weighted equity shares	20000	20000
Nominal value of shares	10	10
Profit/(Loss) after tax attributable to equity share	(13.55)	0.00
Earning per share (Basic)	(67.73)	0.00

ii) Diluted

Number of equity shares as at 01-04-2022	20000	0
Number of equity shares as at 31-03-2023	20000	20000
Number of weighted equity shares	20000	20000
Earning per share (Diluted)	(67.73)	0.00

FOR, RAYZON BIOCARE PVT. LTD.

DIRECTOR

FOR, RAYZON BIOCARE PVT. LTD.

DIRECTOR



RAYZON BIOCARE PRIVATE LIMITED

NOTES TO FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH, 2023

NOTE 25

RELATED PARTY DISCLOSURES

As per Accounting Standard 18, under the Companies (Accounting Standard) Rules, 2021, the discloser of transactions with the related parties as defined in the Accounting Standard and identified by the Company are given below:

i) List of related parties:

a) Associates:

1) Rayzon Solar Pvt. Ltd.

b) Key management personnel and their relatives:

Key management personnel:

1) Chirag Devchandbhai Nakrani

2) Hardik Ashokbhai Kothiya

3) Gaurav Dhirubhai Nekarani

4) Sanketkumar Bharatbhai Kothiya

5) Darshil Bharatbhai Gondaliya

ii) Transactions carried out with related parties in the ordinary course of business during the year:

	2022-23 Rupees	2021-22 Rupees
1 Purchases from associates: Associates:		
1) Rayzon Solar Pvt. Ltd.	2.64	0.00
2 Loans accepted during the year: Key management personnel:		
1) Chirag Devchandbhai Nakrani	34.50	0.00
2) Hardik Ashokbhai Kothiya	34.50	0.00
	69.00	0.00
3 Balance at the end of the year: Loans received: Key management personnel:		
1) Chirag Devchandbhai Nakrani	34.50	0.00
2) Hardik Ashokbhai Kothiya	34.50	0.00
	69.00	0.00

No amounts pertaining to related parties have been provided for as doubtful debts. Also no amounts have been written off or written back during the year.

NOTE 26

OTHER MATTERS

1 In the opinion of the Directors:

a) The current assets and loans and advances are approximately of the value stated, if realised in the ordinary course of business.



FOR, RAYZON BIOCARE PVT. LTD.

[Signature]

DIRECTOR

FOR, RAYZON BIOCARE PVT. LTD.
[Signature]
DIRECTOR

RAYZON BIO CARE PRIVATE LIMITED

NOTES TO FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH, 2023

NOTE 26 (CONTD.)

OTHER MATTERS (CONTD.)


- b The provision for depreciation and for all known liabilities is adequate and not in excess of the amount reasonably necessary.
- 2 There are no imports, expenditure in foreign currencies and earnings in foreign exchange during the year. (Previous year Rs. Nil)
- 3 The Company is operating in a single segment, i.e., Trading of Cosmetic, and accordingly, no separate information for segment-wise disclosure is required as per Accounting Standard 17 on 'Segment Reporting' under the Companies (Accounting Standards) Rules, 2006.
- 4 The Company has no amounts due to suppliers under the Micro, Small and Medium Enterprises Development Act, 2006, [MSMED Act] as at 31st March, 2023. The disclosure pursuant to the said Act is as under:

This information has been determined to the extent such parties have been identified on the basis of information available with the Company.

- 5 The Revised Schedule III has become effective from 1st April, 2021 for the preparation of financial statements. This has significantly impacted the disclosure and presentation made in the financial statements. Previous year's figures have been regrouped / reclassified wherever necessary to correspond with the current year's

As per our report attached to balance sheet

For K D KANANI & CO
Chartered Accountants
Firm Reg No. 147212W


Kaushik D Kanani
Proprietor
M. No. 183787



For and on behalf of the Board


Chirag Devchandbhai Nakrani
Director
DIN: 08589167


Hardik Ashokbhai Kothiya
Director
DIN: 08589174

Place: Surat
Date: September 02, 2023

Place: Surat
Date: September 02, 2023

RAYZON BIOCARE PRIVATE LIMITED

GROUPINGS OF BALANCE SHEET AS AT 31ST MARCH, 2023

	Rupees	Rupees	Rupees
EQUITY AND LIABILITIES			
Share capital:			
20000 Equity shares of Rs. 10 each fully paid-up		200000.00	200000.00
Reserves and surplus:			
Statement of Profit and Loss - surplus:			
Balance as per last balance sheet	0.00		
Less: Loss for the year	(1354612.48)	(1354612.48)	(1354612.48)
Long-term borrowings:			
Unsecured loans:			
Loans and advances from related parties			
From Directors:			
Chirag Devchandbhai Nakrani	3450000.00		
Hardik Ashokbhai Kothiya	3450000.00	6900000.00	6900000.00
Trade payables:			
a) Total outstanding dues of creditors other than micro enterprises and small			
Amazon Seller Services Private Limited	1168.49		
Copyhart	10620.00		
Google India Pvt Ltd	15749.00		
Lash Technologies Private Limited	20250.00		
M.2 Technology	29700.00		
Rayzon Solar Private Limited	26476.00		
Softkarts Infotech	15000.00		
Unpaid audit fees	7500.00		
Unpaid professional fees	15000.00	141463.49	141463.49
(Trade payables exceeding one year Rs.			
Other current liabilities:			
Advances from customers:			
Better Energies LLP	178094.73	178094.73	178094.73
Total			6064945.74

FOR, RAYZON BIOCARE PVT. LTD.

DIRECTOR

FOR, RAYZON BIOCARE PVT. LTD.

DIRECTOR

RAYZON BIOCARE PRIVATE LIMITED

GROUPINGS OF BALANCE SHEET AS AT 31ST MARCH, 2023

	Rupees	Rupees	Rupees
ASSETS			
Property, plant & equipment:			
Tangible assets			
Printer:			
Balance as per last balance sheet	0.00		
Add: Additions during the year	10000.00		
	<u>10000.00</u>		
Less: Depreciation	<u>2872.00</u>	7128.00	
Computer:			
Balance as per last balance sheet	0.00		
Add: Additions during the year	15170.00		
	<u>15170.00</u>		
Less: Depreciation	<u>2599.00</u>	12571.00	19699.00
Deferred tax assets (Net):			
Deferred tax asset:			
Related to property, plant & equipment	114.00	114.00	114.00
Other non-current assets:			
Security deposits:			
Sec. Deposit Against (Barcode Regi.)	3000.00	3000.00	
Others:			
Bank deposits with maturity of more than 12 months:			
HDFC Bank	300000.00		
Add: Accrued interest thereon	3510.00	303510.00	306510.00
Current assets:			
Inventories:			
Stock-in-trade (in respect of goods acquired for trading)	4438402.38	4438402.38	
Trade receivables:			
Considered good - secured:			
Deluce Sale (B2C Small)	1839.00		
Deluce Sale (B2C Small) Other State	1686.55		
Flipkart Sale B2C	28627.67	32153.22	32153.22
Cash and bank balances:			
Cash and cash equivalents:			
Balances with banks:			
Balance in current account:			
HDFC Bank - 50200076742369	20229.00		
ICICI Bank Ltd. - 348005500922	129388.49	149617.49	
Cash on hand	16497.00	166114.49	
Total c/f		<u>4962993.09</u>	

FOR, RAYZON BIOCARE PVT. LTD.

Signature

DIRECTOR

FOR, RAYZON BIOCARE PVT. LTD.

Signature

DIRECTOR

RAYZON BIOCARE PRIVATE LIMITED

GROUPINGS OF BALANCE SHEET AS AT 31ST MARCH, 2023

	Rupees	Rupees	Rupees
Total b/d			4962993.09
Short-term loans and advances:			
Advances to suppliers:			
Bigfoot Retail Solutions Private Limited	3377.65		
Easy Sell Service Pvt. Ltd.	7490.00		
Indo Harbal Product	49508.00	60375.65	60375.65
Other current assets:			
Pre-paid expenses:			
Preliminery Expenses	16400.00	16400.00	
Tax refunds receivable:			
IGST ITC receivable	880583.00		
CGST ITC receivable	71558.00		
SGST ITC receivable	71558.00		
GST cash bal. ledger	732.00		
	1024431.00		
Advance payment of taxes:			
TDS A.Y. 2023-24	746.00		
	746.00	1025177.00	1041577.00
Total			6064945.74

FOR, RAYZON BIOCARE PVT. LTD.

[Signature]

DIRECTOR

FOR, RAYZON BIOCARE PVT. LTD.

[Signature]

DIRECTOR

RAYZON BIOCARE PRIVATE LIMITED

**GROUPINGS OF STATEMENT OF PROFIT AND LOSS FOR THE YEAR ENDED
31ST MARCH, 2023**

	Rupees	Rupees	Rupees
INCOME			
Sale of products:			
Domestic sales		539949.81	539949.81
Other income:			
Interest income			
On bank deposits	3510.00	3510.00	3510.00
Total			543459.81
EXPENSES			
Purchases of stock-in-trade			4837672.12
Changes in stock-inprocess and stock-in-trade:			
Closing stock:			
Stock-in-trade	4438402.38	4438402.38	
Less: Opening stock:			
Stock-in-trade	0.00	0.00	(4438402.38)
Trading expenses			
Freight inward charges		115574.21	115574.21
Employee benefits expenses			
Salary and allowances:			
Employees' salary	24600.00	24600.00	24600.00
Finance costs			
Interest expenses:			
On TDS	2421.00	2421.00	2421.00
Depreciation and amortisation expenses			
Depreciation		5471.00	
Other expenses			
Professional fees		33500.00	
Auditors' remuneration:			
Audit fee	12500.00	12500.00	
Miscellaneous expenses:			
Account management services expens	10000.00		
Bank charges	26.19		
Barcode registration fees	35500.00		
Dia & mould expenses	26500.00		
Kasar vatav	2.04		
Mould development charges	150000.00		
Office expenses	11419.00		
Total c/f	233447.23	46000.00	547335.95

FOR, RAYZON BIOCARE PVT. LTD.

DIRECTOR

FOR, RAYZON BIOCARE PVT. LTD.

[Signature]

DIRECTOR

RAYZON BIO CARE PRIVATE LIMITED

**GROUPINGS OF STATEMENT OF PROFIT AND LOSS FOR THE YEAR ENDED
31ST MARCH, 2023**

	Rupees	Rupees	Rupees
Total b/d	233447.23	46000.00	547335.95
Other expenses(Contd.)			
Miscellaneous expenses:(Contd.)			
Prelimery expenses	4100.00		
Software & web development expense	15000.00		
Stationery and printing	25310.00		
Travelling expenses	2991.50		
Trademark expenses	27000.00	307848.73	
Other selling and distribution expenses:			
Online selling expenses	29048.01		
Influencer marketing expenses	112500.00		
Product camping shoot expenses	595500.00		
Advertisement expenses	259953.60		
	997001.61	997001.61	1350850.34
			<u>1898186.29</u>
Loss before tax			(1354726.48)
Add Tax expenses:			
Deferred tax		(114.00)	(114.00)
Loss after tax			<u>(1354612.48)</u>

FOR, RAYZON BIO CARE PVT. LTD.

[Signature]

DIRECTOR

FOR, RAYZON BIO CARE PVT. LTD.

[Signature]

DIRECTOR